These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18311112)

  • 1. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
    Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
    Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors.
    Jiang SX; Kameya T; Asamura H; Umezawa A; Sato Y; Shinada J; Kawakubo Y; Igarashi T; Nagai K; Okayasu I
    Mod Pathol; 2004 Feb; 17(2):222-9. PubMed ID: 14657947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
    Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas.
    Shida T; Furuya M; Nikaido T; Kishimoto T; Koda K; Oda K; Nakatani Y; Miyazaki M; Ishikura H
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):450-8. PubMed ID: 15701827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung.
    Miki M; Ball DW; Linnoila RI
    Lung Cancer; 2012 Jan; 75(1):58-65. PubMed ID: 21684625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors.
    Taggart MW; Hanna EY; Gidley P; Weber RS; Bell D
    Ann Diagn Pathol; 2015 Jun; 19(3):154-6. PubMed ID: 25892663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
    Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
    Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
    Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.
    Rapa I; Volante M; Migliore C; Farsetti A; Berruti A; Vittorio Scagliotti G; Giordano S; Papotti M
    Prostate; 2013 Aug; 73(11):1241-9. PubMed ID: 23657976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
    Matsumoto Y; Mibu H; Kagebayashi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
    Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
    Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors.
    Ball DW; Azzoli CG; Baylin SB; Chi D; Dou S; Donis-Keller H; Cumaraswamy A; Borges M; Nelkin BD
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5648-52. PubMed ID: 8390674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
    Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
    Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.